EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

Arcutis Biotherapeutics, Inc. (ARQT) had EBITDA of $16.77M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$129.86M
Net Income	$15.01M
Cost of Goods Sold	$10.94M
Gross Profit	$118.92M
Operating Expenses	$113.43M
Operating Income	$16.43M
Non-Operating Income/Expense	$-1.28M
Pre-Tax Income	$15.14M
Normalized Pre-Tax Income	$15.14M
Income after Taxes	$15.01M
Income from Continuous Operations	$15.01M
Consolidated Net Income/Loss	$15.01M
Normalized Income after Taxes	$15.01M
EBIT	$16.43M
EBITDA	$16.77M
Weighted-Average Shares Outstanding (Basic)	130.52M
Weighted-Average Shares Outstanding (Diluted)	135.90M
Earnings per Share (EPS) (Basic)	$0.11
Earnings per Share (EPS) (Diluted)	$0.11
Balance Sheet Financials
Current Assets	$467.67M
Property, Plant, and Equipment	$0.87M
Long-Term Assets	$20.87M
Total Assets	$488.54M
Current Liabilities	$160.34M
Long-Term Debt	$101.95M
Long-Term Liabilities	$107.62M
Total Liabilities	$267.96M
Common Equity	$220.58M
Tangible Shareholders Equity	$206.89M
Shareholders Equity	$220.58M
Common Shares Outstanding	125.59M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$14.88M
Cash Flow from Investing Activities	$-26.56M
Cash Flow from Financial Activities	$3.06M
Beginning Cash	$43.22M
End Cash	$34.43M
Increase/Decrease in Cash	$-8.79M
Stock-Based Compensation	$23.45M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.92
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.32
Debt to Equity Ratio	0.49
Gross Margin	91.58%
Operating Margin	12.65%
EBIT Margin	12.65%
EBITDA Margin	--
Pre-Tax Profit Margin	11.66%
Profit Margin	11.56%
Free Cash Flow	$14.72M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.27
Inventory Turnover	0.28
Receiveable Turnover	0.84
Days Sales in Receivables	107.53
Return on Equity	6.80%
Return on Tangible Equity	7.25%
Return on Assets	3.07%
Return on Investments	4.65%
Book Value Per Share	$1.76
Free Cash Flow per Share	$0.11
Operating Cash Flow per Share	$0.11

Data from Zacks Investment Research, Inc.